Vaxcyte (NASDAQ:PCVX – Get Free Report) had its target price lowered by investment analysts at Needham & Company LLC from ...

Vaxcyte (NASDAQ:PCVX – Get Free Report) had its price target reduced by research analysts at Bank of America from $157.00 to $137.00 in a note issued to investors on Tuesday,Benzinga reports. The ...

Vaccine makers were hit particularly hard yesterday, as Marks’ resignation letter alluded to disagreements with HHS Secretary ...

BofA lowered the firm’s price target on Vaxcyte (PCVX) to $137 from $157 following the company’s report of Phase 2 dose-finding data for VAX-24 ...

Vaxcyte’s stock has dropped around 45% despite a Phase II trial of its invasive pneumococcal disease (IPD) vaccine meeting ...

S&P 500 and Nasdaq hit their six-month low level on Monday as investors’ concerns rise over the upcoming Donald Trump’s ...

Sutro Biopharma, Inc.’s STRO share price has dipped by 10.88%, which has investors questioning if this is right time to buy.

Vaxcyte, Inc.'s stock fell 50% despite positive vaccine results. See how FDA uncertainty, competition, and Phase 3 delays ...

Vaxcyte, Inc.'s positive phase 2 results for VAX-24 show promise in preventing invasive pneumococcal disease in infants.

Needham lowered the firm’s price target on Vaxcyte (PCVX) to $90 from $140 and keeps a Buy rating on the shares after the company announced ...

Starting your week in biotech, shares of San Carlos-based Vaxcyte tumbled on Monday by a whopping 54% after the company reported mixed results from a study of its pneumococcal vaccine in infants. The ...

Biotech stocks were hammered Monday after Peter Marks, a top FDA official, resigned amid a clash with Robert F. Kennedy Jr.